PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.
Frequently asked questions
What sector does PHAXIAM Therapeutics S.A. (PHXM) operate in?
PHAXIAM Therapeutics S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PHAXIAM Therapeutics S.A. (PHXM) current stock price?
As of the latest data, PHAXIAM Therapeutics S.A. stock price is €0.10, with a previous close of €0.10.
What is PHAXIAM Therapeutics S.A. (PHXM) current market capitalization?
PHAXIAM Therapeutics S.A. market cap is approximately 1.01 million.
What is PHAXIAM Therapeutics S.A. (PHXM) Earnings Per Share (EPS)?
The trailing EPS is -€0.98, and the forward EPS is -€0.89.
Does PHAXIAM Therapeutics S.A. (PHXM) pay dividends?
No. PHAXIAM Therapeutics S.A. does not pay a dividend.
What is PHAXIAM Therapeutics S.A. (PHXM) beta (volatility) score?
PHAXIAM Therapeutics S.A. has a beta of 1.742, suggesting it is more volatile than the market.
